J. Jansen

发表

The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories

A. Kohlmann, T. Haferlach, G. Martinelli, 2011, Leukemia.

The ubiquitin ligase Triad1 inhibits myelopoiesis through UbcH7 and Ubc13 interacting domains

P. Jansen, H. Swarts, S. M. Noordermeer, 2009, Leukemia.

Degradable dU-based DNA template as a standard in real-time PCR quantitation

J. Jansen, L. V. D. Locht, E. Mensink, 2001, Leukemia.

IAPs as therapeutic targets in haematological malignancies

J. Jansen, S. Langemeijer, A. D. de Graaf, 2008, Expert opinion on therapeutic targets.

First Meeting on Acute Leukemias with structurally altered core binding factor subunits

C. Bloomfield, I. Touw, J. Jansen, 1997, Leukemia.

Acquired skewing of Lyonization remains stable for a prolonged period in healthy blood donors

E. Stevens-Linders, T. Witte, J. Jansen, 2002, Leukemia.

Inhibitor of apoptosis proteins: new therapeutic targets in hematological cancer?

T. Witte, A. O. Graaf, J. Jansen, 2004, Leukemia.

Gfi1 and Gfi1b: key regulators of hematopoiesis

J. Jansen, B. A. Reijden, L. Meer, 2010, Leukemia.

Ubiquitylation in normal and malignant hematopoiesis: novel therapeutic targets

J. Jansen, J. Marteijn, B. A. Reijden, 2006, Leukemia.

Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34+CD38− cells

M. Raaijmakers, J. Jansen, T. Witte, 2006, Leukemia.